Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting
Relmada Therapeutics Corporate Logo (PRNewsFoto/Relmada Therapeutics, Inc.)
NEWS PROVIDED BY
Relmada Therapeutics, Inc.
Apr 29, 2021, 08:30 ET
Offer THIS ARTICLE
NEW YORK, April 29, 2021/PRNewswire/ – Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology organization tending to infections of the focal sensory system (CNS), today declared that information identified with REL-1017, the organization's lead item competitor, will be introduced in six banners at the 2021 Society of Biological Psychiatry (SOBP) Annual Meeting, which is being held for all intents and purposes between April 29 and May 1, 2021.
Subtleties of the introductions are beneath:
Date/Time: April 29, 2021, from 1:15 – 2:15 PM ET
Banner Number: T142
Title: Esmethadone (REL-1017) Antagonizes NMDA Receptors and Reduces Ca2+ Entry in Presence of Quinolinic Acid and Gentamicin
Meeting: Poster Session I
Date/Time: April 29, 2021, from 1:15 – 2:15 PM ET
Banner Number: T143
Title: Esmethadone (REL-1017) Reduces Glutamate-Induced Currents in NMDA Receptors with the GluN2D Subunit
Meeting: Poster Session I
Date/Time: April 30, 2021, from 1:00 – 2:00 PM ET
Banner Number: F136
Title: Esmethadone (REL-1017) Compares with NMDA Receptor Antagonists in FLIPR Ca2+ Assay
Meeting: Poster Session II
Date/Time: April 30, 2021, from 1:00 – 2:00 PM ET
Banner Number: F137
Title: Esmethadone (REL-1017) Shows Similar Effects to Ketamine in Manual Patch Clamp Studies
Meeting: Poster Session II
Date/Time: May 1, 2021, from 1:30 – 2:30 PM ET
Banner Number: S138
Title: Esmethadone (REL-1017) Restores NMDA Receptor 1 Subunit Expression in an In Vitro Model of Glutamatergic Excitotoxicity
Meeting: Poster Session III
Date/Time: May 1, 2021, from 1:30 – 2:30 PM ET
Banner Number: S143
Title: Esmethadone (REL-1017) Reduces Glutamate-Induced Currents in NMDA Receptors in a Concentration Dependent Manner
Meeting: Poster Session III
About REL-1017
REL-1017, a novel NMDA receptor (NMDAR) channel blocker that specially targets hyperactive channels while keeping up physiological glutamatergic neurotransmission, is entering late-stage concentrates as an adjunctive treatment for MDD in grown-ups. Our clinical program for REL-1017 will assess its potential as the principal fast acting, oral, once-every day energizer treatment. In a Phase 2 preliminary, REL-1017 showed fast beginning and supported energizer impacts with measurably critical upgrades when contrasted with fake treatment. The Phase 2 examination additionally affirmed the positive wellbeing and bearableness profile of REL-1017 saw in recently finished Phase 1 investigations. In April 2017, the FDA allowed Fast Track assignment for REL-1017 for the adjunctive treatment of significant burdensome problem.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology organization tending to illnesses of the focal sensory system (CNS), with an emphasis on significant burdensome issue (MDD). Our accomplished and devoted group is focused on having an effect in the existences of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that specially targets hyperactive channels while keeping up physiological glutamatergic neurotransmission. REL-1017 has entered late-stage advancement as an adjunctive treatment for MDD in grown-ups.
